DermaSensor non-invasively analyzes skin lesions using data from below the skin at the cellular and subcellular levels. [Image courtesy of DermaSensor]
DermaSensor
DermaSensor won top honors at this year’s MedTech Innovator Mid-Stage Companies Pitch Event at DeviceTalks Boston, which drew more than 1,000 applications from medical device startups.
The Miami-based company developed an optical spectroscopy device that can evaluate a skin lesion for cancer risk in under 30 seconds.
“Nearly all of the tens of thousands of skin cancer deaths every year are completely avoidable if they are simply detected early,” DermaSensor CEO Cody Simmons told MassDevice. “That’s what’s exciting about the opportunity — and also a bit of the tragedy and frustration in this field — is that pretty much all skin cancers are curable, and pretty much all skin cancers, you can literally see on the surface of the skin.”
DermaSensor raised $10 million earlier this year in preparation for a commercial launch in the U.S.
DermaSensor won FDA breakthrough device designation in 2021 and expects to be the first FDA-cleared device to assist PCPs in evaluating skin cancer. It would be the only FDA-cleared automated skin cancer detection tool on the market using any kind of imaging or optical technology.
